Literature DB >> 8261463

Expression of bcl-2 in small cell lung carcinoma cells.

N Ikegaki1, M Katsumata, J Minna, Y Tsujimoto.   

Abstract

We have investigated the expression of bcl-2 protein in a panel of small cell lung carcinoma (SCLC) cells lines. Five of six cell lines examined expressed relatively high levels of bcl-2 protein and transcripts. The bcl-2 expression in SCLC cells, however, was not always associated with myc expression. Since dysregulation of bcl-2 may be involved in the course of tumorigenesis and/or in the acquisition of drug resistance of tumor cells, the expression of bcl-2 in SCLC cells may become an important indicator in the prognosis or treatment of SCLC.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8261463

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  58 in total

Review 1.  Small cell lung cancer: past, present, and future.

Authors:  Estelamari Rodriguez; Rogerio C Lilenbaum
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

Review 2.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

3.  Novel systemic therapies for small cell lung cancer.

Authors:  Charles M Rudin; Christine L Hann; Craig D Peacock; D Neil Watkins
Journal:  J Natl Compr Canc Netw       Date:  2008-03       Impact factor: 11.908

4.  Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Authors:  Cleo E Rolle; Rajani Kanteti; Mosmi Surati; Suvobroto Nandi; Immanuel Dhanasingh; Soheil Yala; Maria Tretiakova; Qudsia Arif; Todd Hembrough; Toni M Brand; Deric L Wheeler; Aliya N Husain; Everett E Vokes; Ajit Bharti; Ravi Salgia
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

5.  Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis.

Authors:  Bassant M Barakat; Qi-En Wang; Chunhua Han; Keisha Milum; De-Tao Yin; Qun Zhao; Gulzar Wani; El-Shaimaa A Arafa; Mohamed A El-Mahdy; Altaf A Wani
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 6.  Cellular and molecular biology of small cell lung cancer: an overview.

Authors:  Niki Karachaliou; Sara Pilotto; Chiara Lazzari; Emilio Bria; Filippo de Marinis; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

7.  Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.

Authors:  Yan-qiu Ou; Wen bo Zhu; Yan Li; Peng-xin Qiu; Yi-jun Huang; Jun Xie; Song-min He; Xiao-ke Zheng; Tian-dong Leng; Dong Xu; Guang-mei Yan
Journal:  Acta Pharmacol Sin       Date:  2009-12-07       Impact factor: 6.150

8.  Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.

Authors:  Christine L Hann; Vincent C Daniel; Elizabeth A Sugar; Irina Dobromilskaya; Sara C Murphy; Leslie Cope; Xue Lin; Jared S Hierman; Daniel L Wilburn; D Neil Watkins; Charles M Rudin
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

9.  Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.

Authors:  Wataru Nakajima; Kanika Sharma; Mark A Hicks; Ngoc Le; Rikiara Brown; Geoffrey W Krystal; Hisashi Harada
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

10.  Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

Authors:  Charles M Rudin; Ravi Salgia; Xiaofei Wang; Lydia D Hodgson; Gregory A Masters; Mark Green; Everett E Vokes
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.